LSA
ITCI

Leonteq Securities AG’s Intra-Cellular Therapies Inc. ITCI Stock Holding History

Leonteq Securities AG’s Portfolio ITCI Stock Details ITCI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-16
Closed -$1.34K – 1362
2024
Q4 		$1.34K Sell
16
-485
-97% -$39.9K ﹤0.01% 1178
2024
Q3 		$36.7K Sell
501
-696
-58% -$52.3K ﹤0.01% 818
2024
Q2 		$82K Sell
1,197
-983
-45% -$68.2K 0.01% 659
2024
Q1 		$151K Buy
+2,180
New +$150K 0.01% 558
2023
Q3 		– Sell
-310
Closed -$19.6K – 1305
2023
Q2 		$19.6K Hold
310
– – ﹤0.01% 966
2023
Q1 		$16.8K Hold
310
– – ﹤0.01% 941
2022
Q4 		$16.4K Hold
310
– – ﹤0.01% 994
2022
Q3 		$14.4K Hold
310
– – ﹤0.01% 1004
2022
Q2 		$17.7K Hold
310
– – ﹤0.01% 996
2022
Q1 		$19K Hold
310
– – ﹤0.01% 1014
2021
Q4 		$16.2K Buy
+310
New +$13K ﹤0.01% 1089

Other funds holding ITCI

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $9.85B AUM 55.6% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM
DKCM
Davidson Kempner Capital Management New York $7.33B AUM 56.47% 1-Year Est. Return
UOC
UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

Leonteq Securities AG's ITCI Position: Q1 2025 in Review

Leonteq Securities AG sold out of Intra-Cellular Therapies Inc. (ITCI) in Q1 2025, closing a stake of 16 shares — an estimated $1.34K sold.

Leonteq Securities AG first reported a position in ITCI in Q4 2021 and held it in 11 quarters. The position peaked at $151K in Q1 2024. 395 funds tracked by Wall St. Rank hold ITCI as of Q1 2025.

  • Leonteq Securities AG reported no remaining Intra-Cellular Therapies Inc. position as of Q1 2025 after selling out during the quarter.
  • Leonteq Securities AG sold 16 Intra-Cellular Therapies Inc. shares in Q1 2025, an estimated $1.34K.
  • Leonteq Securities AG first reported a position in Intra-Cellular Therapies Inc. in Q4 2021 and held it in 11 quarters.
  • Leonteq Securities AG's Intra-Cellular Therapies Inc. position peaked at $151K in Q1 2024.
  • 395 funds tracked by Wall St. Rank held Intra-Cellular Therapies Inc. as of Q1 2025.

Based on Leonteq Securities AG's 13F filing for Q1 2025, filed 23 Feb 2026.